Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Phase 2 Recruiting
200 enrolled
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
Recruiting
2,415 enrolled
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Phase 2 Recruiting
60 enrolled
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
Phase 2 Recruiting
286 enrolled
Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
Recruiting
6,035 enrolled
MK-9999-01A
Phase 1/2 Recruiting
90 enrolled
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Phase 1/2 Recruiting
27 enrolled
A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
Phase 2 Recruiting
94 enrolled
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Phase 1/2 Recruiting
289 enrolled
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
Phase 2 Recruiting
98 enrolled
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Phase 1/2 Recruiting
104 enrolled
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Phase 3 Recruiting
750 enrolled
A Study of Avutometinib for People With Solid Tumor Cancers
Phase 1 Recruiting
23 enrolled
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Phase 1/2 Recruiting
147 enrolled
PEDS-PLAN
Phase 2 Recruiting
500 enrolled
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Phase 2 Recruiting
122 enrolled 2 FDA
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
Phase 1 Recruiting
34 enrolled
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
Phase 2 Recruiting
45 enrolled
RISE in HR NBL
Phase NA Recruiting
84 enrolled
GLOW-FISH
Phase 1/2 Recruiting
22 enrolled
SJFAMILY
Recruiting
1,500 enrolled
18F-DOPA II - PET Imaging Optimization
Phase 3 Recruiting
800 enrolled
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Phase 1/2 Recruiting
90 enrolled
SPEARHEAD-3 Pediatric Study
Phase 1/2 Recruiting
20 enrolled
Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II,Multi-center, Clinical Study.
Phase 1/2 Recruiting
125 enrolled
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Phase 2 Recruiting
131 enrolled
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Phase 2 Recruiting
93 enrolled
NB-NK-2026
Phase 3 Recruiting
5 enrolled
SABRE
Phase 1 Recruiting
18 enrolled
BRICCS
Recruiting
40 enrolled
NMTT
Phase 2 Recruiting
441 enrolled
Phase II Study of Proton Radiation Therapy for Neuroblastoma
Phase NA Recruiting
30 enrolled
GPC2
Phase 1 Recruiting
45 enrolled
Aflac-NBL-2002
Phase 1 Recruiting
24 enrolled
Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma
Phase 1/2 Recruiting
42 enrolled
PHOX2B
Phase 1 Recruiting
38 enrolled